BioSpace News Archive

The novel coronavirus is spread easily. Simply being around people dramatically increases the chances of spreading the virus.

Nevro Corp. announced that the underwriter of each of Nevro’s previously announced concurrent public offerings of 1,625,000 shares of its common stock and $165,000,000 aggregate amount of its 2.75% convertible senior notes due 2025 has fully exercised its option to purchase an additional 243,750 shares of Nevro’s common stock at a public offering price of $84.00 per share

The Eurofins’ U.S. Clinical Diagnostics network announced that blood-based antibody testing for Coronavirus SARS-CoV-2 will begin Monday, April 6 at Boston Heart Diagnostics, a Eurofins subsidiary.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees options to purchase an aggregate of 286,000 shares of BioCryst common stock on March 31, 2020 as inducements material to each employee entering into employment with BioCryst.

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its Pure Sunfarms (“PSF”) joint venture has finalized the expansion of its credit facility with its existing lender to $59 million, including accordion provisions of $22.5 million. The expanded credit facility (the “Credit Facility”) consists of a $7.5 million revolving operating loan (the “Revolver”) and a $10 million term loan (the “New Term L

A world-renowned leader in infectious disease and transfusion medicine research, Vitalant Research Institute (VRI)—a division of Vitalant, the nation’s largest independent blood service provider—is helping direct collection and processing of blood plasma donations from recovered COVID-19 patients and developing technologies to det